Estrogen receptor beta (ERb/ESR2) has a central role in mouse ovaries, as ERb knockout (BERKO) mice are subfertile due to an increase in fibrosis around the maturing follicle and a decrease in blood supply. This has a consequence that these follicles rarely rupture to release the mature oocyte. Matrix metalloproteinases (MMPs) are modulators of the extracellular matrix, and the expression of one specific MMP, MMP-19, is normally increased in granulosa cells during their maturation until ovulation. In this study, we demonstrate that MMP-19 levels are downregulated in BERKO mouse ovaries. Using human MCF-7 cells that overexpress ERb, we could identify MMP-19 to be a transcriptional target of ligand-bound activated ERb acting on a specificity protein-1 binding site. These data provide a molecular explanation for the observed follicle rupture defect that contributes to the subfertility of female BERKO mice.
Introduction
Primary targets of the female sex hormone estrogen are the mammary gland and uterus in females. Additionally, estrogen is a modulator of cellular growth and differentiation in both males and females, and essential for maintenance and proper functioning of the bone, cardiovascular system, brain, prostate, breast, urogenital tract, and immune system (Gujar et al. 2013 , Jia et al. 2015 . Estrogen exerts several of its effects through two classical steroid nuclear hormone receptors, estrogen receptor alpha (ERa/ESR1) and estrogen receptor beta (ERb/ESR2). Each receptor mediates very distinct functions of estrogen, which may overlap or oppose each other (Jia et al. 2015) .
Both receptors are required for normal function of the ovary. ERa is expressed in the theca layer and ERb in granulosa cells (Cheng et al. 2002 , Inzunza et al. 2007 . While ERa knockout female mice are completely infertile with hemorrhagic cystic ovaries (Couse et al. 2005) , the female ERb knockout (BERKO) mice are subfertile. The defect in the female BERKO mice has been localized to a late step in follicular maturation and rupture, leading to very rare ovulation in these mice (Krege et al. 1998 , Inzunza et al. 2007 .
Ovulation is a well-defined physiological process regulated by hormones and growth factors culminating in liberation of the mature ovum from the preovulatory follicle into the periovulatory space (Hsueh et al. 1984 , Richards et al. 1987 . A tightly regulated proteolytic degradation of basement membranes and the connective tissue that constitutes the follicle wall is required for successful completion of this process.
The matrix metalloproteinases (MMPs) and their tissue inhibitors of MPs (TIMPs) have been postulated to play a critical role in the extracellular matrix (ECM) remodeling associated with many physiological and pathological processes, such as embryo implantation, inflammation, cancer, follicular development, and ovulation (Alexander & Werb 1992 , Khokha et al. 1995 , Smith et al. 1999 , Curry & Osteen 2003 . The MMPs are a family of extracellular proteinases that can be classified into different subfamilies according to their primary structures, domain organization, cellular localization, and substrate specificity.
Several studies have shown increased MMP-19 expression in periovulatory follicles in mouse and rat ovaries (Hagglund et al. 1999 , Jo & Curry 2004 ). This could be more strongly observed in gonadotropininduced ovaries where MMP-19 and its inhibitor TIMP-1 revealed a different expression pattern compared to the other MMPs and TIMPs that were expressed at a constitutive level throughout the periovulatory period. Both MMP-19 and TIMP-1 mRNA were localized to the granulosa and thecal-interstitial cells of large preovulatory and ovulating follicles (Hagglund et al. 1999) . Findings from these studies indicated important roles for MMP-19 during follicular maturation, ovulation, and luteal regression and encouraged us to investigate whether MMP-19 expression is dysregulated in BERKO mice, which could contribute to the observed subfertility in these mice.
Materials and methods

Animal experiments and ethics statement
Animals used for this study were female BERKO mice and WT littermates obtained from breeding of heterozygous male and female mice. Mice were housed (12 h light:12 h darkness, at a temperature of 21-22 8C, and a relative humidity of 50-62%) in polycarbonate plastic cages (Scambur, Koge, Denmark) containing wood chips bedding with free access to fresh water and food pellets, at the sterile animal facility of Karolinska University Hospital (Huddinge, Sweden). All mice in the BERKO colony, which were originally on a C57BL/6J/129 background, were backcrossed for 11 generations with C57BL/6 mice. Mating and genotyping of WT and BERKO mice as well as the use of mature BERKO and WT female mice as oocyte donors is described earlier (Inzunza et al. 2007) . Ovarian stimulation was performed by one i.p. administration of 5 IU pregnant mare's serum gonadotropin (PMSG, Folligon, Intervet, Sollentuna, Sweden) . After 48 h, the mice were injected intra-peritoneally with the second gonadotropin injection of human chorionic gonadotropin (hCG) 5 IU (Chorulon, Intervet). The female mice were sacrificed either after 12 h by cervical dislocation, and the ovaries were dissected and stored in RNAlater medium (Ambion) at K80 8C for RNA extraction or flash frozen for protein extraction. A total of nine BERKO mice and nine WT mice were sacrificed in three separate experiments.
All animal experiments were performed in accordance with the guidelines and approval of the local ethical committee.
MCF-7 cell culture
MCF-7 human breast adenocarcinoma cells were cultured in DMEM (containing 1 mg/ml glucose) supplemented with 10% FCS (all from Life Technologies). ERb overexpressing MCF-7 cells were generated using the tet-off system (MCF-7-ERb), as described earlier (Papoutsi et al. 2009 ). These cells were cultured as above without 1 mg/ml tetracycline (Sigma) for at least 4 days. ERb levels were monitored by western blot (see below). All cells were cultured at 37 8C and 5% CO 2 in a humidified incubator. When cells were treated with ERa-or ERb-specific ligands (10 nM 4,4 0 ,4 00 -(4-propyl-(1H)-pyrazole-1,3,5-triyl)trisphenol, PPT, or 10 nM 2,3-bis(4-hydroxyphenyl)-propionitrile (DPN), respectively both from Tocris, Bristol, UK), the media was changed to phenol-free DMEM (Life Technologies) supplemented with 5% dextran charcoal-(DCC) treated FCS (Thermo Scientific, Stockholm, Sweden) 3 days prior to ligand treatment (see below).
RNA extraction, RT and quantitative real-time PCR
Total RNA from MCF-7 cells or WT and BERKO ovaries was extracted using the RNeasy mini kit (Qiagen) according to the manufacturer's protocol. Elution of mRNA was performed with 50 ml RNase-free water. cDNA was synthesized from mRNA using the SuperScript III first-strand synthesis system with oligo (dT) 20 primers (Life Technologies). Quantitative real-time PCR (qPCR) measurements were performed using 1 ml cDNA, 200 nM forward and reverse primers (Supplementary Table 1 , see section on supplementary data given at the end of this article), and the SYBR green PCR master mix (Applied Biosystems) according to manufacturer's instructions. qPCRs were setup and run on a 7500 fast real-time PCR system (Applied Biosystems). Each qPCR was performed in triplicates in three different runs with negative controls. Relative mRNA expression was analyzed using the DDC t method normalized to Gapdh levels. Where indicated the cells were treated with DMSO, 10 nM PPT, or 10 nM DPN for 6 h prior to RNA extraction.
Western blot analysis
The ERb antibody was generated by immunizing rabbits with 1 mg purified ERb-ligand-binding domain (LBD) motif (a.a. 320-527, a kind gift from Dr X Lou, Houston Methodist Hospital) divided into four immunizations. The final bleed serum was then purified using ERb-LBD coupled to cyanogen bromide sepharose according to manufacturer's instructions (GE Healthcare). WT and BERKO ovaries were washed in ice-cold PBS and suspended in radioimmunoprecipitation assay lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% (v/v) Nonidet P-40, 0.5% (v/v) Triton X-100, 0.1% sodium deoxycholate, 1 mM Dithiothreitol (DTT), and 1! EDTA-free protease inhibitor cocktail) (Roche). The tissues were homogenized for 20 s in a FastPrep-24 homogenizer (MP Biomedicals), followed by 1 min sonication to shear the DNA. The supernatants were collected by 10 min centrifugation at 10 000 g, C4 8C and stored at K80 8C until use. Similar procedures were followed for MCF-7 cells with the exception that no FastPrep-24 homogenizer was used. In total, 30 mg extracts per lane were separated using SDS-PAGE, and proteins were electrotransferred to a PVDF membrane (Bio-Rad Laboratories), blocked in TBS-T starting block solution (Thermo Scientific), and probed using rabbit anti-human ERb-LBD antibody, rabbit anti-human ERa antibody (MC-20, Santa Cruz Biotechnology), rabbit anti-human MMP-19 antibody (SigmaAldrich), rabbit anti-human TIMP-1 antibody (H-150, Santa Cruz Biotechnology), and mouse anti-human b-actin antibody (Sigma-Aldrich). The bound antibodies were visualized using anti-mouse or anti-rabbit HRP-linked secondary antibody (GE Life Sciences, Uppsala, Sweden) and ECL detection kit (GE Life Sciences). Quantification was performed using the freely available ImageJ software (http://imagej.nih.gov/ij/). Where indicated the cells were treated with DMSO, 10 nM PPT, 10 nM DPN, or 10 mM of the c-Jun inhibitor SP600125 (Tocris) for 72 h prior to cell harvest.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed as described earlier (Tammimies et al. 2012 ) with slight modifications. Briefly, MCF-7 or MCF-7-ERb cells were grown on 15 cm inner diameter culture plates to 80-90% confluency in phenol red-free DMEM supplemented with 5% DCC-treated FCS (Thermo Scientific) for 48 h. After treating with 10 nM DPN, 10 nM PPT, or DMSO for 45 min, cells were washed with PBS, and chromatin was cross-linked for 15 min with 1.5% formaldehyde in PBS. Cells were harvested and nuclear extracts were procured. Chromatin was sonicated using a Bioruptor (Diagenode, Liege, Belgium), and a fraction of the soluble chromatin was put aside as input material. ChIP was performed overnight with 2 mg of the indicated antibodies and magnetic protein sepharose G (Life Technologies). The antibodies were rabbit anti-human ERb-LBD (prepared in-house), rabbit anti-human ERa (MC-20), rabbit anti-human c-Jun (H-79), and normal rabbit IgG (sc-2763) (all from Santa Cruz Biotechnology). After washing, the sepharose beads were eluted three times with 50 ml elution buffer (0.1 M NaHCO 3 , 1% SDS), and bound chromatin was reverse cross-linked overnight at 65 8C. Eluted DNA fragments were isolated and purified using QIAquick PCR purification kit (Qiagen) and analyzed by real-time qPCR normalized to input and relative to IgG (primers listed in Supplementary Table 1) .
Electromobility shift assay
Nuclear extract from MCF-7-ERb cells was prepared, as described previously (Tammimies et al. 2012) . Electromobility shift assay (EMSA) was performed using the EMSA kit from Life Technologies following the manufacturers' instructions with some slight modifications. In brief, indicated amount of nuclear extracts were incubated with gel shift buffer (4% glycerol, 1 mM MgCl 2 , 0.5 mM EDTA, 50 mM Tris-HCl, pH 7.5, and 0.5 mM DTT), 3 pmol annealed probe (Supplementary Table 1) , and 100 nM DPN or PPT, in a total volume of 12 ml. The reaction was incubated for 30 min at 25 8C and then resolved on 6% PAGE. The nucleic acid was visualized using 1! SYBR green solution (EMSA kit, Life Technologies) on the ChemiDoc gel imaging system (Bio-Rad Laboratories). Quantification was done using the ImageJ software (NIH Software).
Statistical analysis
Unless stated otherwise, statistical significance was determined using an unpaired, two-tailed Student's t test, assuming unequal variances (single comparisons), or a one-way ANOVA followed by the Tukey post hoc test (multiple comparisons). Differences were considered significant if the P value was *P!0.05, **P!0.01, and ***P!0.001 for all tests.
Results
MMP-19 levels are downregulated in BERKO mouse ovaries following hCG-induced ovulation
Previous studies show that both ERb and MMP-19 are specifically expressed in the granulosa cells of the follicle (Hagglund et al. 1999 , Inzunza et al. 2007 . With these studies in mind, we set out to determine if MMP-19 levels are lower in BERKO ovaries. To this end, WT and BERKO mice were sacrificed 12 h post hCG treatment, and ovaries were removed for RNA isolation and western blot analysis. Both ERa and ERb were present in the WT ovarian extracts; however, in BERKO ovaries, only ERa was present (Fig. 1A) . Interestingly, MMP-19 mRNA (Fig. 1B) and protein (Fig. 1C ) levels were significantly lower in BERKO ovaries compared to WT ovaries. The levels of the tissue inhibitor of MMP-19, TIMP-1, were also lower in BERKO ovaries, but the difference did not reach significance. Thus, our following studies focused on MMP-19.
MMP-19 levels are increased in MCF-7 cells overexpressing ERb
We next analyzed if MMP-19 levels change in the ERapositive MCF-7 cells generated to overexpress ERb (MCF-7CERb, Fig. 2A ). ERb overexpression alone had no significant effect on MMP-19 protein levels. However, both the ERb-selective agonist DPN and the ERaselective agonist PPT were able to increase MMP-19 protein (Fig. 2B ) and mRNA levels (Fig. 2C) significantly, suggesting that MMP-19 is a target gene for both ERs. (Fig. 3B) , located 1215 bases upstream of the translation start site and 1062 bases upstream of the TSS of the MMP19 gene (AP1/Sp1 site #3).
No ERb enrichment was found in the absence of ligand or upon treatment with PPT. Furthermore, we could not find any ER enrichment at any other analyzed region (data not shown). ERa was enriched at AP1/Sp1 site #3 upon treatment with the ERa-selective agonist PPT. The AP1 complex member, c-Jun, was also enriched at this site upon PPT treatment, suggesting an interaction between ERa and AP1 here. Of note, we could also observe a ligand-independent recruitment of ERa here, which could suggest that ERa may also bind this region without ligand stimulation. On the other hand, ERb only binds to this region in a ligand-(DPN) dependent manner and not via c-Jun but possibly through another transcriptional complex or to another recognition sequence, for example to the Sp1 site. No ER or c-Jun enrichment was found at a non-related sequence containing a serum response factor (SRF)-binding site (Fig. 3B ). This finding was further elaborated in EMSAs using a probe that encompasses the specific AP1 and Sp1 site (Fig. 3C) , and corresponds to the region to which both ERa and ERb bound in the ChIP assay. As expected, DPN treatment resulted in a clear band whose intensity was increased with increasing amounts of MCF-7CERb nuclear extract (Fig. 3D ). This effect was not seen with PPT treatment, which resulted in formation of a complex of roughly similar size but where intensities were comparable to DMSO vehicle treatment alone, suggesting that less complexes are formed or needed to mediate the effect of PPT. The dependence on either AP1 or Sp1 site was analyzed using AP1, Sp1, or AP1-Sp1 mutated probes (Supplementary Table 1 ). As seen in Fig. 3E , DPN treatment increased the complex formation on the non-mutated WT probe. When the AP1 site was mutated to a sequence without a recognition site for a specific transcription factor, we could see a surprising increase in proteins bound to this probe. However, this increase was ligand independent, suggesting that nonspecific factors bind this probe. In contrast, mutation of the Sp1 site abolished the DPN-mediated increase in complex formation, which was also the case when using the AP1-Sp1 mutated probe (Fig. 3E) , although unspecific complexes also appeared to bind this latter probe to some extent both with and without DPN stimulation. Thus, these data point out ERb, and not ERa, as the main isoform driving estrogen-dependent expression of MMP-19 here.
Inhibition of Sp1, but not AP1 binding, abolishes DPN-dependent MMP-19 expression
We then went on to further elucidate the roles of AP1 and Sp1 in mediating the effects of ER on MMP-19 regulation. We treated MCF-7 and MCF-7CERb cells with the c-Jun N-terminal kinase inhibitor SP600125 that abolishes c-Jun phosphorylation and activation, or the Sp1 family inhibitor mithramycin A (MithA). As expected, PPT treatment increased MMP-19 levels (Fig. 4) . However, upon concomitant PPT and SP600125 treatment, the MMP-19 protein levels significantly dropped. This was evident in both MCF-7 and MCF-7CERb cells. On the other hand, MMP-19 levels remained high in DPN-treated MCF-7CERb cells even with SP600125 treatment (Fig. 4) . Treatment of MCF-7C ERb cells with MithA abolished the DPN-mediated increase in MMP-19 levels, but not the PPT-mediated increase (Fig. 4) . These data suggest that the ERamediated MMP-19 expression is likely dependent on the formation of an AP1 complex, whereas the ERb-mediated MMP-19 expression is dependent on Sp1 family transcription factor binding.
In conclusion, we provide evidence that MMP-19 is an ERb target gene, where ERb requires a specific Sp1 site on the MMP-19 promoter to mediate ligand dependent transcription. This provides mechanistic insights into the role of ERb in the granulosa cells of the follicle and provides an explanation to why lack of ERb, but not ERa, results in increased fibrosis and follicular rupture defects.
Discussion
The causes for reduced fertility can be many. Female mice lacking ERb (BERKO) are subfertile. Although the ovarian follicles grow and differentiate initially normally in these mice, the follicles rarely rupture to ovulate, and the BERKO ovaries display fewer corpora lutea (Cheng et al. 2002 , Inzunza et al. 2007 . Previous studies have pointed out a vascularization defect in BERKO ovaries and increased fibrosis in the thecal layers surrounding the maturing follicle (Inzunza et al. 2007) . Interestingly, wedge resection of BERKO ovaries completely, but transiently, restored fertility supposedly through an adequate rush of blood supply, cytokines, and chemokines. Thus, the increased fibrosis in BERKO ovaries is likely the cause for the inadequate blood supply and follicle rupture defect. MMPs are key proteases that regulate deposition of collagen in the ECM of most tissues and inhibit fibrosis (Giannandrea & Parks 2014) . Several MMPs exist in the ovary (MMP-2, MMP-11, MMP-14, and MMP-19) of which only MMP-19 is strongly increased in the granulosa and thecal-interstitial cells of the preovulatory and ovulating follicles (Hagglund et al. 1999 , Jo & Curry 2004 . This increase in MMP-19 expression coincides with the massive surge in preovulatory estrogen levels. Importantly, we see a downregulation of MMP-19 message and protein levels in BERKO ovaries compared to WT ovaries. This could very well explain the increase in fibrous tissue in BERKO ovaries and thus the deregulated blood supply to the follicle and its difficulties to rupture to release the ovum. Our study shows that both ERa and ERb can regulate MMP19 gene expression in a ligand-dependent manner by binding to a promoter sequence of MMP19 Table 1 ). Right panel, quantification (nZ3). AU, arbitrary units, arrowhead indicate probe-binding complexes. *P!0.05 **P!0.01, and ***P!0.001 compared to DMSO treatment and WT probe. 
ERb controls MMP-19 levels in mouse ovaries
encompassing an AP1 and Sp1 binding site. ERa is present in the thecal layer and the stroma, whereas ERb is only present in the granulosa cells of growing and mature follicles (Couse et al. 2005 , Inzunza et al. 2007 . Hence, ERa could modulate the MMP-19 expression in the thecal layer and thereby prevent fibrosis. However, this appears not to be the case or is not sufficient, since ERa is still present in fibrous BERKO ovaries. Instead, our data suggest that it is ERb that drives the MMP-19 expression in the maturing granulosa cells and that lack of this expression results in the described increase in fibrous tissue around the follicle (Inzunza et al. 2007) , thus resulting in a rupture defect of mature follicles.
In our studies, we could observe a ligand-dependent enrichment of ERb to an Sp1 site in the MMP-19 promoter that also encompasses an AP1 site. Sp1 sites are very common in promoter regions, and ERb has been reported to bind tethered to Sp1 in both liganddependent and -independent manner (Kushner et al. 2000 , Safe & Kim 2008 . Nevertheless, direct binding to the DNA cannot be excluded here. In addition, contrary to ERa, ERb does not appear to have a strong preference for a specific consensus sequence and has been shown to bind at distal enhancer sites and intergenic regions to a greater extent than to promoter regions (Vivar et al. 2010) . Therefore, we also cannot exclude other binding sites of ERb that could modulate MMP-19 expression in addition to the one identified in the present study.
In summary, we put forth the evidence that MMP-19 is an ERb target gene in mouse ovaries and that ERb drives its expression in a ligand-dependent fashion. These data explain our previous finding that lack of ERb results in increased fibrosis around the follicle that results in decreased vascularization, a follicle rupture defect, and subfertility. Our data also suggest that ERb could be a promising target in treating subfertility.
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